Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Project to reduce use of animals in vaccine production
Lab mouse
The project could significantly reduce the use of animals in routine vaccine production.
VAC2VAC takes One Health approach to replacing traditional testing methods 

A project which could significantly reduce the use of animals in routine vaccine production will unite some of Europe’s largest pharmaceutical companies.

Funded by the Innovative Medicines Initiative (IMI2), the VAC2VAC project aims to provide data to support the ‘Consistency Approach’ for quality control of vaccines.  Currently, quality control for final products relies on in vivo methods.

A host of organisations from veterinary and human vaccine industry are collaborating in the project, including Zoetis, GlaxoSmithKlein (GSK) and Merial.

To achieve their goal, the organisations will develop, optimise and evaluate physicochemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies.

Noting the importance of this project, Denis Lambrigts from GSK said: “The VAC2VAC project provides a unique platform to support the transition away from in vivo batch release testing for vaccines.

“It brings together both the human and veterinary pharmaceutical industry along with academia and regulators, to build a platform for the development, validation and regulatory acceptance of alternative approaches.

“For industry this is a very positive One Health approach to the challenge of replacement of the long established in vivo test methods and all companies involved are committed to the success off this project.”

Prof. Conrad Hendriksen from Intravacc, one of the key promoters of the project, added: “VAC2VAC takes into account both vaccine safety and animal welfare.

“It will allow us to move away from the traditional paradigm of vaccine batch release testing and to accelerate the introduction of a new paradigm based on innovative non-animal techniques”.

The project is expected to end in 2021 at a total cost of €15.98 million. 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
RCVS Regional Question Time heads to Edinburgh

The RCVS is to bring its Regional Question Time (RQT) to Edinburgh for 2026.

The event will take place at Novotel Edinburgh Park in Edinburgh on Wednesday, 20 May 2026.

It will begin with supper and drinks at 6.30pm, with an evening programme from 7.30pm. This will start with an update on RCVS' activities, followed by questions and answers with representatives.

RCVS is encouraging an 'open dialogue', in which queries can be raised in a friendly, informal environment.

While discussions are expected to be audience-led, the RQT is expected address major issues including the VSA, the CMA's remedy package and the VN Vision project.

Tim Parkin, RCVS president, said: "It's an important time for the professions, and I'm looking forward to meeting colleagues in Scotland as we navigate this period of change together so we can come out stronger."

Tickets can be booked here.